Phio Pharmaceuticals
PHIO
11 hedge funds and large institutions have $277K invested in Phio Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
182% more capital invested
Capital invested by funds: $98.3K → $277K (+$179K)
83% more funds holding
Funds holding: 6 → 11 (+5)
5.59% more ownership
Funds ownership: 3.31% → 8.9% (+5.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$121K |
| 2 |
HF
HRT Financial
New York
|
+$115K |
| 3 |
VF
Virtu Financial
New York
|
+$111K |
| 4 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$35.3K |
| 5 |
Morgan Stanley
New York
|
+$16.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$86.7K |
| 2 |
NA
Nordwand Advisors
Radnor,
Pennsylvania
|
-$1.73K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $80.1K | +$121K | +44,526 | New |
|
|
HF
2
HRT Financial
New York
| $76K | +$115K | +42,338 | New |
|
|
VF
3
Virtu Financial
New York
| $74K | +$111K | +40,910 | New |
|
|
4
Cetera Investment Advisers
Schaumburg,
Illinois
| $23.4K | +$35.3K | +13,000 | New |
|
|
5
Morgan Stanley
New York
| $10.6K | +$16.1K | +5,911 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $8.43K | +$9.53K | +3,508 | +299% |
|
7
UBS Group
Zurich,
Switzerland
| $4.32K | +$1.94K | +712 | +42% |
|
8
Barclays
London,
United Kingdom
| $365 | +$552 | +203 | New |
|
|
SS
9
SBI Securities
Tokyo,
Japan
| $113 | +$171 | +63 | New |
|
|
AWM
10
Activest Wealth Management
Aventure,
Florida
| $16 | – | – | – |
|
11
Bank of America
Charlotte,
North Carolina
| $13 | – | – | – |
|
|
SM
12
Sabby Management
Miami Beach,
Florida
| – | -$86.7K | -25,131 | Closed |
|
|
NA
13
Nordwand Advisors
Radnor,
Pennsylvania
| – | -$1.73K | -500 | Closed |
|
PHIO Hedge Fund Activity: Q4 2024 in Review
11 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2024, worth a combined $277K — up 182% from $98.3K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PHIO positions and 2 closed out — a net gain of 5 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $121K. The largest seller was Sabby Management, exiting entirely with an estimated $86.7K sold.
- 11 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2024, up from 6 in Q3 2024.
- Funds reported $277K of Phio Pharmaceuticals stock for Q4 2024, up 182% quarter-over-quarter.
- 7 funds opened new Phio Pharmaceuticals positions in Q4 2024 and 2 closed out, a net change of +5 holders.
- The largest Phio Pharmaceuticals buyer in Q4 2024 was Citadel Advisors, an estimated $121K added.
- The largest Phio Pharmaceuticals seller in Q4 2024 was Sabby Management, an estimated $86.7K sold.
Based on aggregated 13F filings for Q4 2024.